NCT02502708View on ClinicalTrials.gov

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 12, 2019

Study Completion Date

February 28, 2020

Conditions
Glioblastoma MultiformeGliomaGliosarcomaMalignant Brain TumorEpendymomaMedulloblastomaDiffuse Intrinsic Pontine GliomaPrimary CNS Tumor
Interventions
DRUG

Indoximod

Indoximod will be administered orally twice daily.

DRUG

Temozolomide

Temozolomide will be administered on days 1-5 of every 28 day cycle.

RADIATION

Conformal Radiation

Conformal radiation will be administered on days 3-7 of induction cycle.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered orally daily.

DRUG

Etoposide

Etoposide will be administered orally daily.

Trial Locations (5)

30342

Children's Heathcare of Atlanta, Atlanta

30912

Augusta University, Augusta

32806

Arnold Palmer Hospital for Children, Orlando

55404

Children's Hospitals and Clinics of Minnesota, Minneapolis

80045

Children's Hospital Colorado, Aurora

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02502708 - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | Biotech Hunter | Biotech Hunter